AF
IOVA icon

Amalgamated Financial’s Iovance Biotherapeutics IOVA Stock Holding History

Amalgamated Financial’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$480K Buy
+28,847
New +$446K ﹤0.01% 1529

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Amalgamated Financial's IOVA Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Iovance Biotherapeutics (IOVA) in Q1 2022: 28,847 shares worth $480K. The stake represents ﹤0.01% of the portfolio and ranks #1529 among its holdings.

249 funds tracked by Wall St. Rank hold IOVA as of Q1 2022.

  • Amalgamated Financial held 28,847 shares of Iovance Biotherapeutics worth $480K as of Q1 2022.
  • Iovance Biotherapeutics was a new Amalgamated Financial position in Q1 2022.
  • Iovance Biotherapeutics made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #1529 holding.
  • 249 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.